Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
The aim of this study was to identify predictive risk factors for developing neutropenia after chemotherapy with paclitaxel. We successfully developed a new quantitative method for determination of blood paclitaxel concentration using LC-MS/MS. In clinical study, the wide interindividual variation in molar ratios of plasma 6α-hydroxypaclitaxel/ paclitaxel concentration was seen. More patients are, however, needed to identify predictive risk factors with paclitaxel-based chemotherapy.
|